Latin America Cancer Immunotherapy Market Size & Outlook
Latin America cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Latin America cancer immunotherapy market highlights
- The Latin America cancer immunotherapy market generated a revenue of USD 4,713.7 million in 2023.
- The market is expected to grow at a CAGR of 7.9% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Argentina is expected to register the highest CAGR from 2024 to 2030.
Latin America data book summary
| Market revenue in 2023 | USD 4,713.7 million |
| Market revenue in 2030 | USD 8,018.8 million |
| Growth rate | 7.9% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Latin America region accounted for 3.8% of the global cancer immunotherapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 59,131.5 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.47% in 2023. Horizon Databook has segmented the Latin America cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of cancer and growing demand for advanced treatment strategies are factors expected to drive the growth of the cancer immunotherapy market in Latin America. Moreover, increasing number of private public partnerships to promote research on cancer drug development, along with rising R&D activities and funding for cancer research, is likely to contribute to market growth in this region during the forecast period.
Latin American Cooperative Oncology Group sponsors several clinical assessment and development programs for urothelial cancer. For instance, the organization has initiated a study LACOG 1518 to profile demographic & clinical-pathological characteristics of individuals identified with metastatic/recurrent urothelial cancer in the region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Latin America cancer immunotherapy market size, by country, 2018-2030 (US$M)
Latin America Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
